Abstract
Abstract
Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference14 articles.
1. Cancer statistics, 2019;CA Cancer J Clin,2019
2. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: evidence from a meta-analysis;Medicine,2019
3. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma;Cancer Imaging,2021
4. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course;BMC Cancer,2012
5. Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology;J Natl Compr Canc Netw,2022
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献